Basis of Presentation and Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2025

Accounting Policies [Abstract]

Schedule of segment reporting

Significant segment expenses and segment net loss were as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
Research and development
EO-3021 clinical program	$	3,410	$	2,758
Seribantumab clinical program		60		1,066
Discovery, preclinical, and other unallocated research and development expense		1,425		143
Personnel expenses (including stock-based compensation)		1,981		2,044
General and administrative		3,965		3,858
Restructuring charges		3,375		—
Other segment items(a)		(5)		838
Segment net loss		(14,211)		(10,707)
Reconciliation of segment net loss
Adjustments and reconciling items		—		—
Net loss	$	(14,211)	$	(10,707)
(a) Other segment items in segment net loss includes other income (expense), net and income tax expense.